The fall IPO market kept a brisk pace this past week with 11 IPOs, led by restaurant chain Portillo’s (PTLO). SPACs also stayed active, with 18 blank check IPOs. There was one postponement: winery Winc (WBEV). New filers continue to...read more
Ventyx Biosciences, a Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases, raised $152 million by offering 9.5 million shares at $16, within the range of $15 to $17. The company offered 1.7 million more shares than anticipated...read more
Updated Monday, 10/18. 11 IPOs are slated to raise $2.0 billion led by restaurant chain Portillo’s (PTLO). The diverse group also features investment management software, water pipelines, coconut water, and crypto mining. ...read more
Ventyx Biosciences, a Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases, announced terms for its IPO on Friday. The Encinitas, CA-based company plans to raise $125 million by offering 7.8 million shares at a price range of...read more
US IPO Weekly Recap: Portillo’s gains 87% in an 11 IPO week
The fall IPO market kept a brisk pace this past week with 11 IPOs, led by restaurant chain Portillo’s (PTLO). SPACs also stayed active, with 18 blank check IPOs. There was one postponement: winery Winc (WBEV). New filers continue to...read more
Inflammatory disease biotech Ventyx Biosciences prices upsized IPO at $16 midpoint
Ventyx Biosciences, a Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases, raised $152 million by offering 9.5 million shares at $16, within the range of $15 to $17. The company offered 1.7 million more shares than anticipated...read more
US IPO Week Ahead: Consumer issuers remain active as hot dogs headline an 11 IPO week
Updated Monday, 10/18. 11 IPOs are slated to raise $2.0 billion led by restaurant chain Portillo’s (PTLO). The diverse group also features investment management software, water pipelines, coconut water, and crypto mining. ...read more
Inflammatory disease biotech Ventyx Biosciences sets terms for $125 million IPO
Ventyx Biosciences, a Phase 1 biotech developing selective therapies for inflammatory and autoimmune diseases, announced terms for its IPO on Friday. The Encinitas, CA-based company plans to raise $125 million by offering 7.8 million shares at a price range of...read more